Efficacy and safety of icotinib in treating patients with advanced esophageal squamous cell carcinoma in failure of first-line chemotherapy

LI Hao; BAO Xiaqing; LIU Xianju

doi:10.7619/jcmp.20215138

Journal of Clinical Medicine in Practice > 2022 > 26(13): 105-109. > DOI: 10.7619/jcmp.20215138

LI Hao, BAO Xiaqing, LIU Xianju. Efficacy and safety of icotinib in treating patients with advanced esophageal squamous cell carcinoma in failure of first-line chemotherapy[J]. Journal of Clinical Medicine in Practice, 2022, 26(13): 105-109. DOI: 10.7619/jcmp.20215138

Citation:

PDF (773 KB)

Efficacy and safety of icotinib in treating patients with advanced esophageal squamous cell carcinoma in failure of first-line chemotherapy

Department of Oncology, Affiliated Hospital of Qinghai University, Xining, Qinghai, 810000

More Information

Received Date: December 26, 2021
Available Online: July 01, 2022

Graphical Abstract

Abstract

Abstract

Objective
To explore the efficacy and safety of icotinib as epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in treating patients with advanced esophageal squamous cell carcinoma (ESCC) in failure of first-line chemotherapy.
Methods
A total of 58 advanced ESCC patients failed to first-line chemotherapy (treatment of platinum combined with paclitaxel or fluorouracil) in the Department of Oncology of Affiliated Hospital of Qinghai University from October 2017 to January 2020 were selected as research objects, and the objective response rate (ORR), disease control rate (DCR) and adverse reactions of orally taken of icotinib were analyzed. Kaplan-Meier survival curve was used to calculate the progression free survival (PFS) and overall survival (OS).
Results
Among the 58 advanced ESCC patients with icotinib therapy, 4 cases (6.9%) achieved complete remission (CR), 20 cases (34.5%) achieved partial remission (PR), 21 cases (36.2%) achieved stable disease (SD), and 13 cases (22.4%) developed into tumor progression (PD); the ORR and DCR were 41.4% (24/58) and 77.6% (45/58) respectively. The median PFS was 5.6 months (95%CI, 1.6 to 9.6) and the median OS was 18.5 months (95%CI, 10.2 to 26.8). Fatigue (34.5%), nausea and vomiting (29.3%) and diarrhea (20.7%) were the most common adverse reactions during treatment.
Conclusion
Icotinib has good therapeutic effect and safety in treating advanced ESCC patients failed to first-line chemotherapy, which may delay tumor progression and further improve the survival benefit of patients.
- esophageal squamous cell carcinoma,
- first-line chemotherapy,
- icotinib,
- epidermal growth factor receptor,
- tyrosine kinase inhibitor,
- efficacy,
- safety

FullText(HTML)

References (28)

References

[1]	SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2020[J]. CA a Cancer J Clin, 2020, 70(1): 7-30. doi: 10.3322/caac.21590
[2]	SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA a Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
[3]	FENG R M, ZONG Y N, CAO S M, et al. Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?[J]. Cancer Commun (Lond), 2019, 39(1): 22. doi: 10.1186/s40880-019-0368-6
[4]	刘曙正, 于亮, 陈琼, 等. 2003—2012年食管癌高发区林州市不同病理类型食管癌发病及生存状况分析[J]. 中华预防医学杂志, 2017, 51(5): 393-397. doi: 10.3760/cma.j.issn.0253-9624.2017.05.005
[5]	LIN Y, TOTSUKA Y, HE Y, et al. Epidemiology of esophageal cancer in Japan and China[J]. J Epidemiol, 2013, 23(4): 233-242. doi: 10.2188/jea.JE20120162
[6]	LEE S J, KIM S, KIM M, et al. Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase Ⅱ study[J]. BMC Cancer, 2015, 15: 693. doi: 10.1186/s12885-015-1716-9
[7]	YAMASAKI M, YASUDA T, YANO M, et al. Multicenter randomized phase Ⅱ study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003)[J]. Ann Oncol, 2017, 28(1): 116-120. doi: 10.1093/annonc/mdw439
[8]	FANG M, SONG T, LIANG X D, et al. Comparative study of cisplatin-based definitive concurrent chemoradiotherapy with S-1 versus paclitaxel for unresectable locally advanced esophageal squamous cell carcinoma[J]. Oncotarget, 2017, 8(23): 37080-37090. doi: 10.18632/oncotarget.16180
[9]	NISHIMURA Y, HIRAOKA M, KOIKE R, et al. Long-term follow-up of a randomized Phase Ⅱstudy of cisplatin/5-FU concurrent chemoradiotherapy for esophageal cancer (KROSG0101/JROSG021)[J]. Jpn J Clin Oncol, 2012, 42(9): 807-812. doi: 10.1093/jjco/hys112
[10]	HONG L, HAN Y, BRAIN L. Epidermal growth factor receptor: an important target in esophageal cancer[J]. Expert Opin Ther Targets, 2013, 17(10): 1179-1185. doi: 10.1517/14728222.2013.820709
[11]	SHARMA B, SINGH V J, CHAWLA P A. Epidermal growth factor receptor inhibitors as potential anticancer agents: an update of recent progress[J]. Bioorg Chem, 2021, 116: 105393. doi: 10.1016/j.bioorg.2021.105393
[12]	HE J, SU C, LIANG W, et al. Icotinib versus chemotherapy as adjuvant treatment for stage Ⅱ-ⅢA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial[J]. Lancet Respir Med, 2021, 9(9): 1021-1029. doi: 10.1016/S2213-2600(21)00134-X
[13]	XU L, QI Q, ZHANG Y, et al. Combination of icotinib and chemotherapy as first-line treatment for advanced lung adenocarcinoma in patients with sensitive EGFR mutations: A randomized controlled study[J]. Lung Cancer, 2019, 133: 23-31. doi: 10.1016/j.lungcan.2019.05.008
[14]	LI X, ZHANG L, DA J, et al. Routine-dose and high-dose icotinib in patients with advanced non-small cell lung cancer harboring EGFR exon 21-L858R mutation: the randomized, phase II, INCREASE trial[J]. Clin Cancer Res, 2020, 26(13): 3162-3171. doi: 10.1158/1078-0432.CCR-19-3064
[15]	EISENHAUER E A, THERASSE P, BOGAERTS J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1. 1)[J]. Eur J Cancer, 2009, 45(2): 228-247. doi: 10.1016/j.ejca.2008.10.026
[16]	TROTTI A, COLEVAS AD, SETSER A, et al. CTCAE v3. 0: development of a comprehensive grading system for the adverse effects of cancer treatment[J]. Semin Radiat Oncol, 2003, 13(3): 176-181. doi: 10.1016/S1053-4296(03)00031-6
[17]	KOTECKI N, HIRET S, ETIENNE P L, et al. First-line chemotherapy for metastatic esophageal squamous cell carcinoma: clinico-biological predictors of disease control[J]. Oncology, 2016, 90(2): 88-96. doi: 10.1159/000442947
[18]	HIRAMOTO S, KATO K, SHOJI H, et al. A retrospective analysis of 5-fluorouracil plus cisplatin as first-line chemotherapy in the recent treatment strategy for patients with metastatic or recurrent esophageal squamous cell carcinoma[J]. Int J Clin Oncol, 2018, 23(3): 466-472. doi: 10.1007/s10147-018-1239-x
[19]	SHALATA W, JACOB B M, AGBARYA A. Adjuvant Treatment with Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor Mutated Non-Small-Cell Lung Carcinoma Patients, Past, Present and Future[J]. Cancers (Basel), 2021, 13(16): 14754.
[20]	MOK T S, CHENG Y, ZHOU X D, et al. Updated overall survival in a randomized study comparing dacomitinib with gefitinib as first-line treatment in patients with advanced non-small-cell lung cancer and EGFR-activating mutations[J]. Drugs, 2021, 81(2): 257-266. doi: 10.1007/s40265-020-01441-6
[21]	XIE C, JING Z, LUO H, et al. Chemoradiotherapy with extended nodal irradiation and/or erlotinib in locally advanced oesophageal squamous cell cancer: long-term update of a randomised phase 3 trial[J]. Br J Cancer, 2020, 123(11): 1616-1624. doi: 10.1038/s41416-020-01054-6
[22]	石远凯, 孙燕, 丁翠敏, 等. 中国埃克替尼治疗非小细胞肺癌专家共识(2015版)[J]. 中国肺癌杂志, 2015, 18(7): 397-400. https://www.cnki.com.cn/Article/CJFDTOTAL-FAIZ201507001.htm
[23]	ZENG Z, YAN B, CHEN Y, et al. Survival benefit and toxicity profile of adjuvant icotinib for patients with EGFR mutation-positive non-small cell lung carcinoma: a retrospective study[J]. Transl Lung Cancer Res, 2020, 9(6): 2401-2410. doi: 10.21037/tlcr-20-1214
[24]	LIANG S, XU Y, TAN F L, et al. Efficacy of icotinib in advanced lung squamous cell carcinoma[J]. Cancer Med, 2018, 7(9): 4456-4466. doi: 10.1002/cam4.1736
[25]	LIU K, JIANG G, ZHANG A, et al. Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer[J]. BMC Cancer, 2020, 20(1): 76. doi: 10.1186/s12885-020-6543-y
[26]	LIU Y, ZHANG Y, FENG G, et al. Comparison of effectiveness and adverse effects of gefitinib, erlotinib and icotinib among patients with non-small cell lung cancer: A network meta-analysis[J]. Exp Ther Med, 2017, 14(5): 4017-4032.
[27]	SHI Y, ZHANG L, LIU X, et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial[J]. Lancet Oncol, 2013, 14(10): 953-961. doi: 10.1016/S1470-2045(13)70355-3
[28]	HUANG J, FAN Q, LU P, et al. Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: A Single-Arm, Multicenter Phase 2 Study[J]. J Thorac Oncol, 2016, 11(6): 910-917. doi: 10.1016/j.jtho.2016.02.020

[1]	YANG Lei, FENG Yi, WANG Yang. Correlation between preoperative coagulation function and prognosis in patients with hypertensive cerebral hemorrhage undergoing emergency craniotomy[J]. Journal of Clinical Medicine in Practice, 2024, 28(8): 83-87. DOI: 10.7619/jcmp.20240214
[2]	Yisilamujiang·TUERXUN, LI Yuanming, Yelibo·JUNUSIHAN, LIU Wenjuan, ZOU Anqing, Mayirimu·SAIMAITI, CHEN Jiahua. Relationships of coagulation and fibrinolytic functions with patent foramen ovale complicated with cryptogenic stroke[J]. Journal of Clinical Medicine in Practice, 2023, 27(21): 116-119, 124. DOI: 10.7619/jcmp.20231661
[3]	LIU Wei, ZHANG Naiying. Effect of thrombelastogram in monitoring hemostatic and coagulation function in patients undergoing elective orthopedic surgery during blood transfusion[J]. Journal of Clinical Medicine in Practice, 2020, 24(20): 11-14. DOI: 10.7619/jcmp.202020003
[4]	ZHU Wenjuan. Effect of octreotide combined with pantoprazole for elderly patients with peptic ulcer complicating upper gastrointestinal bleeding and its influence on coagulation function[J]. Journal of Clinical Medicine in Practice, 2019, 23(22): 55-57. DOI: 10.7619/jcmp.201922019
[5]	LIU Haodong, FU Xiaowu. Effect of whole-course epidural labor analgesia on coagulation function during vaginal delivery in pregnant women with hypertension[J]. Journal of Clinical Medicine in Practice, 2019, 23(21): 98-100. DOI: 10.7619/jcmp.201921028
[6]	ZHANG Guotao, QIAO Xueli, ZHANG Mingxing. Effect of blood type on coagulation function in parturient women of child-bearing age[J]. Journal of Clinical Medicine in Practice, 2018, (9): 121-123. DOI: 10.7619/jcmp.201809035
[7]	ZHOU Haizhou, HUANG Qianjie, JIANG Hui. Effect of acute super volume blood dilution on cardiac output and blood coagulation function in the senile patients[J]. Journal of Clinical Medicine in Practice, 2017, (3): 123-124,132. DOI: 10.7619/jcmp.201703037
[8]	ZHU Jinli. Effect of urinary kallidinogenase combined with troxerutin and cerebroprotein hydrolysate injection on coagulation and neurological function of patients with acute cerebral infarction[J]. Journal of Clinical Medicine in Practice, 2016, (9): 17-20. DOI: 10.7619/jcmp.201609005
[9]	LIU Yingying, SUN Qiushi. Change of coagulation function and influence of chemotherapy on coagulation function in elderly patients with non-small cell lung cancer[J]. Journal of Clinical Medicine in Practice, 2014, (3): 90-92. DOI: 10.7619/jcmp.201403030
[10]	LI Xiulan. Changes and clinical significances of the blood coagulation function in patients with malignant tumor[J]. Journal of Clinical Medicine in Practice, 2013, (11): 162-164. DOI: 10.7619/jcmp.201311069

Cited By

Cited by

Periodical cited type(9)

1.	何瑷芯，赵利华，单俊堂，邹卓成，黄瑜，宁少丽，黄鼎坚. 基于正交设计探讨温和灸对青年人心血管功能及心率变异性的影响. 河北中医. 2025(01): 125-131+136 .
2.	程玲，汪芳，王伟，谈芮. 多元家庭参与计划下链式亲情护理对老年心血管疾病手术患者的影响. 齐鲁护理杂志. 2024(02): 56-59 .
3.	王彩霞，薛燕文，吴骏，孙志辉，杜勇平. 社区-家庭一体化的Ⅲ期心脏康复对老年冠心病患者自我效能及运动能力的影响. 检验医学与临床. 2024(02): 166-169 .
4.	赵汐冉，高寒，武子敬，薛桐，胡泽兵，张舒，郭显. 鸢尾素减轻模拟失重下心肌细胞氧化应激和细胞凋亡. 空军军医大学学报. 2024(02): 152-157+162 .
5.	袁悦雯，褚欣秋，李阳. 虚拟现实技术在心脏康复运动处方中的应用. 心脑血管病防治. 2024(11): 32-36+41 .
6.	叶赟，杨柳，张婷，熊朝叶. 分级康复疗养对高海拔地区心血管疾病疗养员心境状态植物神经功能及预后的影响. 安徽医学. 2023(05): 556-560 .
7.	崔荣，张姝，吴丽英，付琳，张思宁. 运动康复治疗对老年慢性心衰患者生活质量的影响评价. 中外医疗. 2023(14): 36-39+44 .
8.	牛田瑶，储祥玲，龚倩. 基于运动的心脏康复治疗冠心病的病理生理学研究进展. 中华物理医学与康复杂志. 2023(10): 948-952 .
9.	林宁宁，赵佳佳，樊俊雅，田欣雨，张辉. 3种治疗方案对经皮冠状动脉介入术患者心功能及预后的影响. 实用临床医药杂志. 2022(16): 66-70 . 本站查看

Other cited types(4)

Get Citation

PDF

XML

Article views (168) PDF downloads (8) Cited by(13)

Turn off MathJax

Article Contents

Abstract

References

Efficacy and safety of icotinib in treating patients with advanced esophageal squamous cell carcinoma in failure of first-line chemotherapy